VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure

Withdrawn before enrolling · Phase 4

Conditions studied: Heart Failure Congestive

In brief

This trial is seeking to determine whether a single 4mg intranasal dose of bumetanide acutely reduces pulmonary artery pressure and blood volume in the outpatient setting for patients with heart failure and an implanted device for remote patient monitoring (i.e. Cordella or CardioMEMS).

Key facts

Study ID

NCT07375212

Run by

Prisma Health-Upstate

People needed

0

Starts

2026-01-21

Expected to finish

2026-01-21

Last updated by the study team

2026-01-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥ 18 y with chronic HF (NYHA II-III).
• Successful CardioMEMS or Cordella implantation ≥ 3 months prior.
• Clinically mild or worse congestion (no IV diuretics within 7 days).
• eGFR ≥ 20 mL/min/1.73 m²; serum K⁺ 3.5-5.2 mmol/L.

You may not qualify if…

• SBP < 90 mmHg, HR < 50 bpm, or > 110 bpm at baseline.
• Acute HF hospitalization < 30 days.
• Chronic nasal pathology or recent intranasal surgery.
• Known allergy to bumetanide or sulfamides.
• Pregnancy or lactation.
• Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device which has not reached its primary endpoint.

Where it is running

• Prisma Health — Greenville, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.